Insufficient scRNA-seq data for expression of UGT1A9 at single-cell level.
Insufficient scRNA-seq data for expression of UGT1A9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 98% | 586.78 | 222 / 226 | 61% | 36.00 | 248 / 406 |
kidney | 97% | 3032.11 | 86 / 89 | 54% | 45.64 | 484 / 901 |
intestine | 35% | 13.84 | 340 / 966 | 0% | 0.02 | 1 / 527 |
bladder | 33% | 7.86 | 7 / 21 | 0% | 0.04 | 1 / 504 |
esophagus | 9% | 1.29 | 124 / 1445 | 0% | 0 | 0 / 183 |
stomach | 4% | 0.51 | 13 / 359 | 0% | 0 | 0 / 286 |
prostate | 3% | 0.70 | 7 / 245 | 0% | 0 | 0 / 502 |
breast | 1% | 0.40 | 6 / 459 | 0% | 0 | 0 / 1118 |
peripheral blood | 1% | 0.29 | 8 / 929 | 0% | 0 | 0 / 0 |
adipose | 1% | 0.26 | 10 / 1204 | 0% | 0 | 0 / 0 |
thymus | 1% | 0.09 | 4 / 653 | 0% | 0 | 0 / 605 |
skin | 1% | 0.12 | 11 / 1809 | 0% | 0 | 0 / 472 |
spleen | 0% | 1.20 | 1 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0.05 | 1 / 258 | 0% | 0 | 0 / 230 |
pancreas | 0% | 0.03 | 1 / 328 | 0% | 0 | 0 / 178 |
lung | 0% | 0.03 | 1 / 578 | 0% | 0.01 | 1 / 1155 |
heart | 0% | 0.04 | 2 / 861 | 0% | 0 | 0 / 0 |
uterus | 0% | 0 | 0 / 170 | 0% | 0.06 | 1 / 459 |
blood vessel | 0% | 0.01 | 1 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 0% | 0 | 0 / 705 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 180 | 0% | 0 | 0 / 430 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0052697 | Biological process | xenobiotic glucuronidation |
GO_0051552 | Biological process | flavone metabolic process |
GO_0001889 | Biological process | liver development |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0052696 | Biological process | flavonoid glucuronidation |
GO_0042573 | Biological process | retinoic acid metabolic process |
GO_0052695 | Biological process | cellular glucuronidation |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0015020 | Molecular function | glucuronosyltransferase activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0001972 | Molecular function | retinoic acid binding |
Gene name | UGT1A9 |
Protein name | UDP-glucuronosyltransferase 1A9 (UGT1A9) (EC 2.4.1.17) (UDP-glucuronosyltransferase 1-9) (UDPGT 1-9) (UGT1*9) (UGT1-09) (UGT1.9) (UDP-glucuronosyltransferase 1-I) (UGT-1I) (UGT1I) (lugP4) UDP-glucuronosyltransferase variant (EC 2.4.1.17) UDP-glucuronosyltransferase UDP-glucuronosyltransferase 1A9 UDP-glucuronosyltransferase (EC 2.4.1.17) |
Synonyms | GNT1 hCG_2039726 UGT1 |
Description | FUNCTION: [Isoform 1]: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile . Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds . Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol and estrone . Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties . Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II . Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan . Also metabolizes mycophenolate, an immunosuppressive agent . .; FUNCTION: [Isoform 2]: Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1. . |
Accessions | Q4R0Z7 Q5DSZ5 O60656 A9UKF4 Q53E75 A9UKF7 Q4R0Z6 Q330M4 ENST00000354728.5 [O60656-1] |